Immunogenic compound comprising immunogenic fragment of apolipoprotein B100, immunogenic composition comprising the same and use thereof

Specific ApoB100 epitopes in an immunogenic composition induce an immune response to reduce lipid levels and associated diseases, enhancing weight loss and maintaining therapeutic effects by combining with GLP-1R agonists, addressing the limitations of existing cholesterol vaccines.

KR1020260112920APending Publication Date: 2026-07-21CNBD CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
KR1020260004591
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-01-10
Filing Date
2026-01-09
Publication Date
2026-07-21

AI Technical Summary

Technical Problem

Existing technologies lack an effective ApoB100 epitope with immunogenicity to reduce cholesterol levels and address conditions related to lipid metabolism, such as arteriosclerosis.

Method used

Development of specific peptide fragments of ApoB100 epitopes, including residues 2205-2210, 3662-3688, and 3380-3394, or variants with at least 60% sequence identity, which can induce an immune response to ApoB100, potentially reducing lipid levels and associated diseases when administered in an immunogenic composition.

Benefits of technology

The immunogenic compounds effectively induce an immune response, reducing ApoB100 levels, improving obesity and related conditions like fatty liver disease, cardiovascular disease, and atherosclerosis, while avoiding the yo-yo effect of rapid weight gain by combining with GLP-1R agonists.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.
Need to check novelty before this filing date? Find Prior Art